Skip to main content

Grant Angus's Form 4 filing

Teva Pharmaceutical Industries Ltd (TEVA) · filed Aug 13, 2024

Accession no.
0000950170-24-096182
Filed
Aug 13, 2024
Trade date
Aug 9, 2024
Filing delay
4 days
Rule 10b5-1 plan
Checked

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $70.2K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Grant AngusCIK 0001988830Officer (EVP, Business Development)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 9, 2024Ordinary SharesMOption exerciseAcquired+12,913–F2–12,913Direct
Aug 9, 2024Ordinary SharesSSaleDisposed−4,065$17.28−$70,243.28,848Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 9, 2024Ordinary SharesMOption exerciseDisposed−12,913$0.00$038,739Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)